Chemical radiosensitizers for use in radiotherapy - PubMed (original) (raw)
Review
. 2007 Aug;19(6):397-417.
doi: 10.1016/j.clon.2007.03.010. Epub 2007 May 2.
Affiliations
- PMID: 17478086
- DOI: 10.1016/j.clon.2007.03.010
Review
Chemical radiosensitizers for use in radiotherapy
P Wardman. Clin Oncol (R Coll Radiol). 2007 Aug.
Abstract
Radiosensitizers are intended to enhance tumour cell killing while having much less effect on normal tissues. Some drugs target different physiological characteristics of the tumour, particularly hypoxia associated with radioresistance. Oxygen is the definitive hypoxic cell radiosensitizer, the large differential radiosensitivity of oxic vs hypoxic cells being an attractive factor. The combination of nicotinamide to reduce acute hypoxia with normobaric carbogen breathing is showing clinical promise. 'Electron-affinic' chemicals that react with DNA free radicals have the potential for universal activity to combat hypoxia-associated radioresistance; a nitroimidazole, nimorazole, is clinically effective at tolerable doses. Hypoxia-specific cytotoxins, such as tirapazamine, are valuable adjuncts to radiotherapy. Nitric oxide is a potent hypoxic cell radiosensitizer; variations in endogenous levels might have prognostic significance, and routes to deliver nitric oxide specifically to tumours are being developed. In principle, many drugs can be delivered selectively to hypoxic tumours using either reductase enzymes or radiation-produced free radicals to activate drug release from electron-affinic prodrugs. A redox-active agent based on a gadolinium chelate is being evaluated clinically. Pyrimidines substituted with bromine or iodine are incorporated into DNA and enhance free radical damage; fluoropyrimidines act by different mechanisms. A wide variety of drugs that influence the nature or repair of DNA damage are being evaluated in conjunction with radiation; it is often difficult to define the mechanisms underlying chemoradiation regimens. Drugs being evaluated include topoisomerase inhibitors (e.g. camptothecin, topotecan), and the hypoxia-activated anthraquinone AQ4N; alkylating agents include temozolomide. Drugs involved in DNA repair pathways being investigated include the potent poly(ADP ribose)polymerase inhibitor, AG14,361. Proteins involved in cell signalling, such as the Ras family, are attractive targets linked to radioresistance, as are epidermal growth factor receptors and linked kinases (drugs including vandetanib [ZD6,474], cetuximab and gefitinib), and cyclooxygenase-2 (celecoxib). The suppression of radioprotective thiols seems to offer more potential with alkylating agents than with radiotherapy, although it remains a strategy worthy of exploration.
Similar articles
- Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M, Van Esch G, Engels B, Verovski V, Storme G. De Ridder M, et al. Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Bull Cancer. 2008. PMID: 18390408 Review. - Radiation sensitization with redox modulators: a promising approach.
Rosenberg A, Knox S. Rosenberg A, et al. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):343-54. doi: 10.1016/j.ijrobp.2005.10.013. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414370 Review. - Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV. Wilson WR, et al. Radiat Res. 2007 Jun;167(6):625-36. doi: 10.1667/RR0807.1. Radiat Res. 2007. PMID: 17523848 - Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.
Adams GE. Adams GE. Radiat Res. 1992 Nov;132(2):129-39. Radiat Res. 1992. PMID: 1438693 Review. - AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH, McKeown SR. Patterson LH, et al. Br J Cancer. 2000 Dec;83(12):1589-93. doi: 10.1054/bjoc.2000.1564. Br J Cancer. 2000. PMID: 11104551 Free PMC article. Review.
Cited by
- Evaluating deposited radiation energy amount and collision quantities of small-molecule radiosensitizers through Monte Carlo simulations.
ALMisned G, Kilic CS, Almansoori A, Mesbahi A, Hamad M, Tekin HO. ALMisned G, et al. Heliyon. 2024 Jun 28;10(13):e33734. doi: 10.1016/j.heliyon.2024.e33734. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050474 Free PMC article. - Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts.
Liu H, Wang Q, Lan W, Liu D, Huang J, Yao J. Liu H, et al. Invest New Drugs. 2024 Aug;42(4):405-417. doi: 10.1007/s10637-024-01451-1. Epub 2024 Jun 17. Invest New Drugs. 2024. PMID: 38880855 - A Phase I Trial of a Methionine Restricted Diet with Concurrent Radiation Therapy.
Mattes MD, Koturbash I, Leung CN, Wen S, Jacobson GM. Mattes MD, et al. Nutr Cancer. 2024;76(6):463-468. doi: 10.1080/01635581.2024.2340784. Epub 2024 Apr 9. Nutr Cancer. 2024. PMID: 38591931 Clinical Trial. - Surprising Radiolytic Stability of 8-Thiomethyladenine in an Aqueous Solution.
Datta M, Szczyrba A, Zdrowowicz M, Wyrzykowski D, Ciupak O, Demkowicz S, Izadi F, Denifl S, Rak J. Datta M, et al. J Phys Chem B. 2024 Apr 18;128(15):3621-3630. doi: 10.1021/acs.jpcb.4c01033. Epub 2024 Apr 5. J Phys Chem B. 2024. PMID: 38578255 Free PMC article. - Advances of hafnium based nanomaterials for cancer theranostics.
Wang J, Pan J, Tang Y, Chen J, Fei X, Xue W, Liu X. Wang J, et al. Front Chem. 2023 Nov 24;11:1283924. doi: 10.3389/fchem.2023.1283924. eCollection 2023. Front Chem. 2023. PMID: 38075497 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials